The Global Cancer Immunotherapy Market is valued at US$153.30 billion in 2025 and is expected to reach US$324.89 billion by 2034, expanding at a CAGR of 8.6% from 2025 to 2034. Growing adoption of immune-based cancer treatments, personalized therapies, and combination approaches is supporting market expansion.

Cancer Immunotherapy Market Overview

Cancer immunotherapy includes treatments that activate, stimulate, or modify the immune system to identify and destroy cancer cells. The market covers immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, cytokine-based therapies, CAR-T and TIL therapies, and oncolytic viruses.

Immunotherapy is being developed across multiple cancer types, including melanoma, lung cancer, breast cancer, blood cancers, colorectal cancer, prostate cancer, and other solid tumors. Increasing focus on personalized treatment and biomarker-driven therapy is also creating opportunities for next-generation immunotherapies.

Key Factors Driving Market Growth

Key factors supporting the growth of the cancer immunotherapy market include:

• Increasing adoption of immune checkpoint inhibitors and combination therapies.
• Growing development of personalized cancer vaccines and mRNA-based immunotherapies.
• Expansion of cellular therapies such as CAR-T and TIL treatments.
• Increasing use of biomarker-based treatment approaches.
• Continued regulatory approvals for new immunotherapy indications and cancer types.
• Development of therapies designed to address resistance to existing treatments.

Regional Market Analysis

North America: The region is supported by expanding FDA-approved immunotherapies and increasing investment in checkpoint inhibitors, cellular therapies, cancer vaccines, and combination treatments. The Cancer Research Institute reported 13 U.S. FDA cancer immunotherapy approvals in 2025, bringing the cumulative total over 14 years to 156. In August 2026, Replimune’s RP1 (Tudriqev) received FDA approval in combination with Opdivo for melanoma after prior treatment.

Europe: European growth is supported by biomarker-based treatment and expanded immunotherapy indications. In May 2026, the EMA’s CHMP issued an opinion supporting expanded Keytruda use in muscle-invasive bladder cancer and additional patient populations. In June 2026, Enhertu received EU approval as a tumor-agnostic HER2-directed therapy for previously treated HER2-positive metastatic solid tumors.

Recent Developments

• Merck & Moderna: On August 19, 2026, the companies reported positive Phase 3 results for personalized mRNA cancer vaccine intismeran autogene (V940) with Keytruda in high-risk melanoma. The combination reduced the risk of recurrence or death by 49%.
• BioNTech: On August 28, 2026, BioNTech announced the end of a Phase 2 trial of its mRNA cancer vaccine autogene cevumeran following an independent safety review.

Market Segmentation

• By Cancer Type
• By Therapy Type
• By Route of Administration
• By End User
• By Distribution Channel

Get the Complete Market Research Report

Access the complete Global Cancer Immunotherapy Market Research Report for detailed market size analysis, segmentation, regional insights, competitive developments, and growth opportunities.

Source: RNP Market Research